MedTrace Logo

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)

NCT02953301 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 201

Last updated 2024-08-30

No results posted yet for this study

Summary

The purpose of this study is to determine whether resminostat will be able to delay or prevent worsening of disease in patients with advanced stage mycosis fungoides or Sézary Syndrome that have recently achieved disease control with previous systemic therapy.

Conditions

  • Mycosis Fungoides
  • Sezary Syndrome
  • Lymphoma, T-Cell, Cutaneous

Interventions

DRUG

resminostat

DRUG

Placebo

Sponsors & Collaborators

  • 4SC AG

    lead INDUSTRY

Principal Investigators

  • Rudolf Stadler, Prof. · Johannes Wesling Klinikum, Minden, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2023-03-31
Completion
2024-08-31

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Greece
  • Italy
  • Japan
  • Netherlands
  • Poland
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02953301 on ClinicalTrials.gov